Is the price fair?
What HALO's price assumes
Halozyme Therapeutics, Inc. trades at 37.9× earnings against 31.5× for the median Biotechnology name, more expensive than its own group.
37.9
Trailing P/E · Biotechnology median 31.5 · 1.20× the median: the market pays up for this one
- Price / sales
- 5.26
Price / sales · as of 2026-Q1
- Free cash flow yield
- 7.8%
Free cash flow yield · Biotechnology median 2.4%
- Growth the price implies
- −0.18%
Growth the price implies · The price pays for −0.18% free cash flow growth a year for a decade; the business has delivered +36% a year over the last three.
Details›
- Price / book2026-Q1
- 36.2
- EV / EBIT2026-Q1
- 18.7
- EV / sales2026-Q1
- 6.34
- Healthcare median P/E362 names
- 29.9
- Biotechnology median P/E158 names
- 31.5
- Free cash flow, trailing twelve months
- $668M
- Market capitalisation
- $8.62B
- 3-year revenue growth
- +29%
- 3-year free cash flow growth
- +36%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $50.35 |
| Its own P/E history, median | $53.87 |
| Its own P/E history, upper quartile | $71.38 |
| 52-week range | $61.63 – $110.73 |
| Today | $108.34 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.